CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
BLA 125268

PROPRIETARY NAME REVIEW(S)
Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology

Date: February 27, 2008

To: Rafael Rieves, MD
Acting Director, Division of Medical Imaging and Hematology
HFD-160

Through: Kellie Taylor, Pharm D, MPH, Team Leader
Denise Toyer, Pharm D, Deputy Director
Carol Holquist, RPh, Director
Division of Medication Errors and Technical Support, HFD 420

From: Richard Abate, RPh, MS, Safety Evaluator
Division of Medication Errors and Technical Support, HFD 420

Subject: Proprietary Name Review for Nplate

Drug Name(s): Nplate (romiplostim) for Injection

Application Type/Number: BLA 125268

Applicant: Amgen, Inc

OSE RCM #: 2007-2549

*** Note: This review contains proprietary and confidential information that should not be released to the public.***
## CONTENTS

EXECUTIVE SUMMARY .................................................................................................................. 3  
1 BACKGROUND ............................................................................................................................. 3  
1.1 Introduction ............................................................................................................................ 3  
1.2 Product Information ............................................................................................................... 3  
2 METHODS AND MATERIALS ....................................................................................................... 4  
2.1 Search Criteria ...................................................................................................................... 5  
2.2 CDER Expert Panel Discussion ............................................................................................ 6  
2.3 Safety Evaluator Risk Assessment of the Proposed Proprietary Name .................................. 6  
3 RESULTS ..................................................................................................................................... 9  
3.1 Database and Information Sources ....................................................................................... 9  
3.2 CDER Expert Panel Discussion ............................................................................................ 9  
3.3 Safety Evaluator Risk Assessment ........................................................................................ 9  
4 DISCUSSION ............................................................................................................................... 10  
5 CONCLUSIONS and RECOMMENDATIONS ............................................................................ 11  
5.1 Comments to the Division ...................................................................................................... 11  
5.2 Comments to the Applicant .................................................................................................. 11  
6 REFERENCES .............................................................................................................................. 12  
6.1 Reviews ................................................................................................................................. 12  
6.2 Databases .............................................................................................................................. 12  
APPENDICES ................................................................................................................................. 15
EXECUTIVE SUMMARY

The results of the Proprietary Name Risk Assessment found that the proposed name, Nplate, has some similarity to other proprietary and established drug names, but the findings of the FMEA indicates that Nplate does not appear to be vulnerable to name confusion that could lead to medication errors from a sound-alike/look-alike perspective. DMETS and DDMAC also evaluated the concern brought forth by the Division of Medical Imaging and Hematology Products that “N” represents normal or normalization. DDMAC did not find the ‘N’ misleading or promotional, and DMETS believes as long as the ‘N’ on the container label and carton labeling is revised to appear in the same color and font as the remainder of the name that this along with the dosing information in the insert labeling will result in the ‘N’ not being problematic. (See Section 5.1.)

1 BACKGROUND

1.1 INTRODUCTION

This review is in response to a request from the Division of Medical Imaging and Hematology Products to evaluate the proposed proprietary name for its potential to contribute to medication errors. The proprietary name, Nplate, is evaluated to determine if the name could be potentially confused with other proprietary or established drug names. DMETS previously reviewed the proprietary name, Nplate, without objection in OSE review # 2006-591, dated February 9, 2007. The proposed labels and labeling for Nplate (romiplostim) for injection were reviewed in OSE review # 2007-2249, dated January 9, 2008.

In addition, DMETS was asked by the Division of Medical Imaging and Hematology Products on January 28, 2008 to evaluate the use of ‘n’ in the name as referring to Normal or Normalizing of platelets as a source of medication error with this product.

1.2 PRODUCT INFORMATION

Nplate is an Fc-peptide fusion protein that increases platelet production. Nplate (romiplostim) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia purpura who have a spleen and do not respond to corticosteroids or immunoglobulin or have had a splenectomy.

The starting adult dose of Nplate is 1 mcg/kg given subcutaneously once weekly. The dose is adjusted to achieve and maintain a platelet count of 50 x 10^9/L. The platelet count requires weekly monitoring prior to each dose. The dose should be increase by 1 mcg/kg if the patient’s platelet count is less than 50 x 10^9/L. If the patient’s platelet count is between 200 x 10^9/L and 400 x 10^9/L, the dose is held until the patient’s platelet count fall below 200 x 10^9/L, and the dose is decreased by 1 mcg/kg. The doses ranged during clinical trials from 1 mcg/kg to 7 mcg/kg with median doses of 2 mcg/kg for patients with a spleen and 3 mcg/kg for patients post splenectomy. The maximum dose of Nplate is 10 mcg/kg given subcutaneously once weekly. Nplate should be discontinued if there is not an increase in the platelet count after four weeks on the 10 mcg/kg dose.
Nplate vials are available in two strengths, 250 mcg and 500 mcg. The product is a lyophilized cake requiring reconstitution with sterile water for injection prior to administration. The 250 mcg vial is reconstituted with 0.72 mL of sterile water to achieve an extractable solution of 250 mcg/0.5 mL. The 500 mcg vial is reconstituted with 1.2 mL of sterile water to achieve an extractable solution of 500 mcg/mL.

2 METHODS AND MATERIALS

FDA’s Proprietary Name Risk Assessment considers the potential for confusion between the proposed proprietary name, Nplate, and the proprietary and established names of drug products existing in the marketplace and those pending IND, NDA, and ANDA products currently under review by the Agency.

For the proprietary name, Nplate, the medication error staff of DMETS search a standard set of databases and information sources to identify names with orthographic and phonetic similarity (see Sections 2.1.1 for detail) and held an CDER Expert Panel discussion to gather professional opinions on the safety of the proposed proprietary name (see Section 2.2).

The Safety Evaluator assigned to the Proprietary Name Risk Assessment is responsible for considering the collective findings, and provides an overall risk assessment of the proposed proprietary name (see detail 2.3). The overall risk assessment is based on the findings of a Failure Modes and Effects Analysis (FMEA) of the proprietary name, and is focused on the avoidance of medication errors. FMEA is a systematic tool for evaluating a process and identifying where and how it might fail. 1 FMEA is used to analyze whether the drug names identified with look- or sound-alike similarity to the proposed name could cause confusion that subsequently leads to medication errors in the clinical setting. DMETS defines a medication error as any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. 2 DMETS uses the clinical expertise of the medication error staff to anticipate the conditions of the clinical setting that the product is likely to be used in based on the characteristics of the proposed product.

In addition, the product characteristics provide the context for the verbal and written communication of the drug names and can interact with the orthographic and phonetic attributes of the names to increase the risk of confusion when there is overlap, or, in some instances, decrease the risk of confusion by helping to differentiate the products through dissimilarity. As such, the Staff considers the product characteristics associated with the proposed drug throughout the risk assessment, since the product characteristics of the proposed may provide a context for communication of the drug name and ultimately determine the use of the product in the usual clinical practice setting.

Typical product characteristics considered when identifying drug names that could potentially be confused with the proposed drug name include, but are not limited to established name of the proposed product, the proposed indication, dosage form, route of administration, strength, unit of

---

measure, dosage units, recommended dose, typical quantity or volume, frequency of administration, product packaging, storage conditions, patient population, and prescriber population. Because drug name confusion can occur at any point in the medication use process, DMETS considers the potential for confusion throughout the entire U.S. medication use process, including drug procurement, prescribing and ordering, dispensing, administration, and monitoring the impact of the medication.  

2.1 Search Criteria

The Medication Error Staff consider the spelling of the name, pronunciation of the name when spoken, and appearance of the name when scripted as outlined in Appendix A.

For this review, particular consideration was given to drug names beginning with the letter ‘N’ when searching to identify potentially similar drug names, as 75% of the confused drug names reported by the USP-ISMP Medication Error Reporting Program involve pairs beginning with the same letter.  

To identify drug names that may look similar to Nplate, the Staff also consider the other orthographic appearance of the name on lined and unlined orders. Specific attributes taken into consideration include the length of the name (six letters), upstrokes (three, capital letter ‘N’, ‘I’, and ‘T’), downstrokes (one, ‘P’), cross-strokes (none), and dotted letters (none). Additionally, several letters in Nplate may be vulnerable to ambiguity when scripted, including the letter ‘N’ may appear as ‘M’; lower case ‘n’ may appear as a lower case ‘h’, ‘r’, ‘u’, or ‘v’; lower case ‘p’ may appear as a lower case ‘y’, ‘ja’ or ‘jo’; a lower case ‘I’ may appear as a ‘b’; a lower case ‘a’ may appear as a lower case ‘o’ or ‘u’; and a lower case ‘e’ may appear as a lower case ‘i’. As such, the Staff also considers these alternate appearances when identifying drug names that may look similar to Nplate.

When searching to identify potential names that may look or sound similar to Nplate, the Medication Error Staff search for names with similar number of syllables (two), stresses (EN-plate or en-PLATE), and placement of vowel and consonant sounds. The Applicant’s intended pronunciation of the proprietary name could not be expressly taken into consideration, as this was not provided with the proposed name submission.

The Staff also consider the product characteristics associated with the proposed drug throughout the identification of similar drug names, since the product characteristics of the proposed drug ultimately determine the use of the product in the clinical practice setting. For this review, the Medication Error Staff were provided with the following information about the proposed product: the proposed proprietary name (Nplate), the established name (romiplostim), proposed indication (Immune or Idiopathic Thrombocytopenia Purpura), strength (250 mcg and 500 mcg), dose (start at 1 mcg/kg per dose, average dose 2-3 mcg/kg per dose, titrate up to 10 mcg/kg per dose based on clinical response), frequency of administration (weekly), route (subcutaneous injection) and dosage form of the product (vial containing a solid cake for injection). Appendix

---


A provides a more detailed listing of the product characteristics the Medication Error Staff general take into consideration.

Lastly, the Medication Error Staff also consider the potential for the proposed name to inadvertently function as a source of error for reasons other than name confusion. Post-marketing experience has demonstrated that proprietary names (or components of the proprietary name) can be a source of error in a variety of ways. As such, these broader safety implications of the name are considered and evaluated throughout this assessment and the Medication Error Staff provide additional comments related to the safety of the proposed name or product based on their professional experience with medication errors.

2.1.1 Data base and information sources

The proposed proprietary name, Nplate, was provided to the medication error staff of DMETS to conduct a search of the internet, several standard published drug product reference texts, and FDA databases to identify existing and proposed drug names that may sound-alike or look-alike to Nplate using the criteria outlined in Appendix A. A standard description of the databases used in the searches is provided in Section 7. To complement the process, the Medication Error Staff use a computerized method of identifying phonetic and orthographic similarity between medication names. The program, Phonetic and Orthographic Computer Analysis (POCA), uses complex algorithms to select a list of names from a database that have some similarity (phonetic, orthographic, or both) to the trademark being evaluated. Lastly, the Medication Error Staff review the USAN stem list to determine if any USAN stems are present within the proprietary name. The findings of the individual Safety Evaluators were then pooled and presented to the Expert Panel.

2.2 CDER EXPERT PANEL DISCUSSION

An Expert Panel Discussion is held by DMETS to gather CDER professional opinions on the safety of the product and the proprietary name, Nplate. Potential concerns regarding drug marketing and promotion related to the proposed names are also discussed. This group is composed of DMETS Medication Errors Prevention Staff and representatives from the Division of Drug Marketing, Advertising, and Communications (DDMAC).

The pooled results of the medication error staff were presented to the Expert Panel for consideration. Based on the clinical and professional experiences of the Expert Panel members, the Panel may recommend the addition of names, additional searches by the Safety Evaluator to supplement the pooled results, or general advice to consider when reviewing the proposed proprietary name.

2.3 SAFETY EVALUATOR RISK ASSESSMENT OF THE PROPOSED PROPRIETARY NAME

Based on the criteria set forth in Section 2.1.1, the Safety Evaluator Risk Assessment applies their individual expertise gained from evaluating medication errors reported to FDA to conduct a Failure Modes and Effects Analysis and provide an overall risk of name confusion. Failure Mode and Effects Analysis (FMEA) is a systematic tool for evaluating a process and identifying where and how it might fail.\(^6\) When applying FMEA to assess the risk of a proposed proprietary

name, DMETS seeks to evaluate the potential for a proposed name to be confused with another drug name as a result of the name confusion and cause errors to occur in the medication use system. FMEA capitalizes on the predictable and preventable nature of medication errors associated with drug name confusion. FMEA allows the Agency to identify the potential for medication errors due to look- or sound-alike drug names prior to approval, where actions to overcome these issues are easier and more effective than remedies available in the post-approval phase.

In order to perform an FMEA of the proposed name, the Safety Evaluator must analyze the use of the product at all points in the medication use system. Because the proposed product is not yet marketed, the Safety Evaluator anticipates the use of the product in the usual practice settings by considering the clinical and product characteristics listed in Appendix A. The Safety Evaluator then analyzes the proposed proprietary name in the context of the usual practice setting and works to identify potential failure modes and the effects associated with the failure modes.

In the initial stage of the Risk Assessment, the Safety Evaluator compares the proposed proprietary name to all of the names gathered from the above searches, expert panel evaluation, and studies, and identifies potential failure modes by asking: "Is the name Nplate convincingly similar to another drug name, which may cause practitioners to become confused at any point in the usual practice setting?" An affirmative answer indicates a failure mode and represents a potential for Nplate to be confused with another proprietary or established drug name because of look- or sound-alike similarity. If the answer to the question is no, the Safety Evaluator is not convinced that the names posses similarity that would cause confusion at any point in the medication use system and the name is eliminated from further review.

In the second stage of the Risk Assessment, all potential failure modes are evaluated to determine the likely effect of the drug name confusion, by asking "Could the confusion of the drug names conceivably result in medication errors in the usual practice setting?" The answer to this question is a central component of the Safety Evaluator's overall risk assessment of the proprietary name. If the Safety Evaluator determines through FMEA that the name similarity would ultimately not be a source of medication errors in the usual practice setting, the name is eliminated from further analysis. However, if the Safety Evaluator determines through FMEA that the name similarity could ultimately cause medication errors in the usual practice setting, the Safety Evaluator will then recommend that an alternate proprietary name be used. In rare instances, the FMEA findings may provide other risk-reduction strategies, such as product reformulation to avoid an overlap in strength or an alternate modifier designation may be recommended as a means of reducing the risk of medication errors resulting from drug name confusion.

DMETS will object to the use of proposed proprietary name when the one or more of the following conditions are identified in the Safety Evaluator's Risk Assessment:

1. DDMAC finds the proposed proprietary name misleading from a promotional perspective, and the review Division concurs with DDMAC's findings. The Federal Food, Drug, and Cosmetic Act provides that labeling or advertising can misbrand a product if misleading representations are made or suggested by statement, word, design, device, or any combination thereof, whether through a trade name or otherwise. [21 U.S.C. 321(n); see also 21 U.S.C. 352(a) & (n)].
2. DMETS identifies that the proposed proprietary name is misleading because of similarity in spelling or pronunciation to another proprietary or established name of a different drug or ingredient [CFR 201.10(C)(5)].

3. FMEA identifies potential for confusion between the proposed proprietary name and other proprietary or established drug names, and demonstrates that medication errors are likely to result from the drug name confusion under the conditions of usual clinical practice.

4. The proposed proprietary name contains an USAN stem, particularly in a manner that is contradictory to the USAN Council’s definition.

5. Medication Error Staff identify a potential source of medication error within the proposed proprietary name. The proprietary name may be misleading, or inadvertently introduce ambiguity and confusion that leads to errors. Such errors may not necessarily involve confusion between the proposed drug and another drug product.

In the event that DMETS objects to the use of the proposed proprietary name, based upon the potential for confusion with another proposed (but not yet approved) proprietary name, DMETS will provide a contingency objection based on the date of approval: whichever product is awarded approval first has the right to the use the name, while DMETS will recommend that the second product to reach approval seek an alternative name.

If none of these conditions are met, then DMETS will not object to the use of the proprietary name. If any of these conditions are met, then DMETS will object to the use of the proprietary name. The threshold set for objection to the proposed proprietary name may seem low to the Applicant; however, the safety concerns set forth in criteria 1 through 5 are supported either by FDA Regulation or by external healthcare authorities, including the IOM, WHO, JCAHO, and ISMP, have examined medication errors resulting from look- or sound-alike drug names and called for Regulatory Authorities to address the issue prior to approval.

Furthermore, DMETS contends that the threshold set for the Proprietary Name Risk Assessment is reasonable because proprietary drug name confusion is a predictable and preventable source of medication error that, in many instances, can be identified and remedied prior to approval to avoid patient harm.

Additionally, post-marketing experience has demonstrated that medication errors resulting from drug name confusion are notoriously difficult to remedy post-approval. Educational efforts and so on are low-leverage strategies that have proven to have limited effectiveness at alleviating the medication errors involving drug name confusion. Higher-leverage strategies, such as drug name changes, have been undertaken in the past; but at great financial cost to the Applicant, and at the expense of the public welfare, not to mention the Agency’s credibility as the authority responsible for the approving the error-prone proprietary name. Moreover, even after Applicant’s have changed a product’s proprietary name in the post-approval phase, it is difficult to eradicate the original proprietary name from practitioner’s vocabulary, and as such, the Agency has continued to receive reports of drug name confusion long after a name change in some instances. Therefore, DMETS believes that post-approval efforts at reducing name confusion errors should be reserved for those cases in which the potential for name confusion could not be predicted prior to approval (see limitations of the process).
If DMETS objects to a proposed proprietary name on the basis that drug name confusion could lead to medication errors, the FMEA process is used to identify strategies to reduce the risk of medication errors. DMETS is likely to recommend that the Applicant select an alternative proprietary name and submit the alternate name to the Agency for DMETS to review. However, in rare instances FMEA may identify plausible strategies that could reduce the risk of medication error of the currently proposed name, and so DMETS may be able to provide the Applicant with recommendations that reduce or eliminate the potential for error would render the proposed name acceptable.

3 RESULTS

3.1 DATABASE AND INFORMATION SOURCES

DMETS conducted a search of the internet, several standard published databases and information sources (see Section 7 References) for existing drug names which sound-alike or look-alike to Nplate to a degree where potential confusion between drug names could occur and result in medication errors in the usual clinical practice settings. In total, three names were identified as having some orthographic similarity to the name Nplate.

These include: Cylate®, —— and Zylate.

3.2 CDER EXPERT PANEL DISCUSSION

On December 27, 2007, the Expert Panel reviewed the pool of names identified by DMETS staff (see section 3.1.1 above), and noted no additional names thought to have orthographic similarity to Nplate. On January 31, 2008, the Expert Panel commented the Safety Evaluator should include a determination of what ‘N’ represents as an abbreviation in the name risk assessment.

On both of the above dates, DDMAC had no concerns regarding the proposed name from a promotional perspective, and did not offer any additional comments relating to the proposed name.

3.3 SAFETY EVALUATOR RISK ASSESSMENT

Independent searches by the primary Safety Evaluator identified an additional name thought to look similar to Nplate and represent a potential source of drug name confusion. The name is Refludan. As such, a total of four names were analyzed to determine if the drug names could be confused with Nplate and if the drug name confusion would likely result in a medication error.

This analysis determined that the name similarity between Nplate and the identified names was unlikely to result in medication errors for four products. One identified name (Zylate) is used for a product marketed only in foreign countries, and thus determined by FMEA to pose minimal risk for error in the usual practice setting (Appendix B).

For two of the names identified (Cylate and ——), FMEA determined that medication errors were unlikely because the products do not overlap in strength or dosage with Nplate and have minimal orthographic and/or phonetic similarity to Nplate (Appendix C).

""Note: This is proprietary and confidential information that should not be released to the public.""
The remaining name (Refludan) has numerical overlap with Nplate in strength, but analysis of the failure mode did not determine the effect of this similarity to result in medication errors in the usual practice setting (see Appendix D). Orthographic differences between these names stem from the fact Refludan contains two additional letters compared to Nplate providing it with added length and orthographic differentiation.

Additionally, the letter ‘N’ was found to be an abbreviation for ‘norm’ or ‘normal’ in medical practice. DMETS review of the labels and labeling, OSE review # 2007-2249, revealed the ‘N’ in the proposed name Nplate was proposed to be a different color font (red) and therefore may be more prominent compared to the remainder of the name (in blue). DMETS recommended this presentation be revised so the name is presented in a single color. (See images in Appendix E.)

4 DISCUSSION

The results of the Proprietary Name Risk Assessment found that the proposed name, Nplate, has some similarity to other proprietary and established drug names, but the findings of the FMEA indicates that the proposed name does not appear to be vulnerable to name confusion that could lead to medication errors from a sound-alike/look-alike perspective.

When evaluating the Division’s concern regarding the use of the ‘N’ as the beginning letter in the proposed name, DMETS identified the letter ‘N’ as representing “norm” or “normal” in medical abbreviation references. We also noted the original presentation of the name on the container label and carton labeling. Additionally, the proposed Insert Labeling defines the goal platelet levels as $50 \times 10^9/L$, and the monitoring information included in the labeling provides prescribers guidance on how and when to adjust the dose of Nplate if the patient should exceed goal platelet levels. Therefore, DMETS believes the Insert Labeling provides prescribers sufficient information to minimize the risk of prescribers unnecessarily increasing the dose of Nplate to achieve a goal of “normal” platelet count. To help further minimize any possible misinterpretation, DMETS believes the ‘N’ should appear in the same color and font size as the remainder of the name. This recommendation was communicated to the applicant on February 26, 2008, but revised labels have not been submitted at the time of this review.

The findings of the Proprietary Name Risk Assessment are based upon current understanding of factors that contribute to medication errors involving name confusion. Although we believe the findings of the Risk Assessment to be robust, our findings do have limitations. First, because our assessment involves a limited number of practitioners, it is possible that the analysis did not identify a potentially confusing name. Also, there is some possibility that our Risk Assessment failed to consider a circumstance in which confusion could arise. However, DMETS believes

---

8 Davis, N, Medical Abbreviations: 26,000 Conveniences at the expense of communication and Safety, 12th Edition, 2005.
that these limitations are sufficiently minimized by the use of an Expert Panel and the CDER Prescription Studies that involved 123 CDER practitioners which was evaluated in OSE review # 2006-591.

However, our risk assessment also faces limitations beyond the control of the Agency. First, our risk assessment is based on current health care practices and drug product characteristics, future changes to either could increase the vulnerability of the proposed name to confusion. Since these changes cannot be predicted for or accounted by the current Proprietary Name Risk Assessment process, such changes limit our findings. To help counterbalance this impact, DMETS recommends that the proprietary name be re-submitted for review if approval of the product is delayed beyond 90 days.

5 CONCLUSIONS AND RECOMMENDATIONS

The Proprietary Name Risk Assessment findings indicate that the proposed name, Nplate, does not appear to be vulnerable to name confusion that could lead to medication errors nor that the use of ‘N’ could be construed as promotional or misleading to healthcare providers to mean normal or normalized. As such, DMETS does not object to the use of the proprietary name, Nplate, for this product.

5.1 COMMENTS TO THE DIVISION

DMETS has no objections to the use of the proprietary name, Nplate, for this product. However, if any of the proposed product characteristics as stated in this review are altered prior to approval of the product, DMETS rescinds this Risk Assessment finding, and recommends that the name be resubmitted for review. In the event that our Risk Assessment finding is rescinded, the evaluation of the name on resubmission is independent of the previous Risk Assessment, and as such, the conclusions on re-review of the name are subject to change. Additionally, if the product approval is delayed beyond 90 day from the date of this review, the proposed name must be resubmitted for evaluation.

The name risk assessment did not identify any names that would make the name vulnerable from a sound or look-alike prospective. In evaluating the name with the Division’s concern that ‘N’ could be interpreted as normal or normalized, our analysis determined that this was a low likelihood. This is mainly because the insert labeling submitted January 14, 2008 contains goal platelet counts, monitor parameters, and directions to adjust doses for the prescribers using Nplate to follow.

DMETS would appreciate feedback of the final outcome of this review. We would be willing to meet with the Division for further discussion, if needed. Please copy DMETS on any communication to the sponsor with regard to this review. If you have further questions or need clarifications, please contact Janet Anderson, project manager, at 301-796-0675.

5.2 COMMENTS TO THE APPLICANT

DMETS has no objections to the use of the proprietary name, Nplate, for this product. However, DMETS reiterates this presentation be revised so the entire name is presented in a single color.
and font in the labels and labeling. DMETS noted the original presentation of the name on the container label and carton labeling. DMETS believes that this presentation is likely to increase potential for caregivers to attempt to achieve normal platelet values in patients and thus increase the risk of adverse events associated with Nplate. DMETS reiterates this presentation be revised so the entire name is presented in a single color and font in the labels and labeling.

Overall, our Risk Assessment is limited by our current understanding of medication errors and causality. The successful application of Failure Modes and Effect Analysis depends upon the learning gained for a spontaneous reporting program. It is quite possible that our understanding of medication error causality would benefit from unreported medication errors; and, that this understanding could have enabled the Staff to identify vulnerability in the proposed name, packaging, and labeling that was not identified in this assessment. To help minimize this limitation in future assessments, we encourage the Applicant to provide the Agency with medication error reports involving their marketed drug products regardless of adverse event severity.

6 REFERENCES

6.1 REVIEWS


6.2 DATABASES

1. *Micromedex Integrated Index (http://weblern/)*

Contains a variety of databases covering pharmacology, therapeutics, toxicology and diagnostics.

2. *Phonetic and Orthographic Computer Analysis (POCA)*

As part of the name similarity assessment, proposed names are evaluated via a phonetic/orthographic algorithm. The proposed proprietary name is converted into its phonemic representation before it runs through the phonetic algorithm. Likewise, an orthographic algorithm exists which operates in a similar fashion. This is a database which was created for DMETS, FDA.

3. *Drug Facts and Comparisons, online version, St. Louis, MO (http://weblern/)*

Drug Facts and Comparisons is a compendium organized by therapeutic Course; contains monographs on prescription and OTC drugs, with charts comparing similar products.

4. *AMF Decision Support System [DSS]*

DSS is a government database used to track individual submissions and assignments in review divisions.
5. **Division of Medication Errors and Technical Support proprietary name consultation requests**

This is a list of proposed and pending names that is generated by DMETS from the Access database/tracking system.

6. **Drugs@FDA** ([http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm](http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm))

Drugs@FDA contains most of the drug products approved since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present. Drugs@FDA contains official information about FDA approved brand name and generic drugs and therapeutic biological products; prescription and over-the-counter human drugs and therapeutic biologics, discontinued drugs and "Chemical Type 6" approvals.

7. **Electronic online version of the FDA Orange Book** ([http://www.fda.gov/cder/ob/default.htm](http://www.fda.gov/cder/ob/default.htm))

Provides a compilation of approved drug products with therapeutic equivalence evaluations.

8. **WWW location** [http://www.uspto.gov](http://www.uspto.gov)

Provides information regarding patent and trademarks.

9. **Clinical Pharmacology Online** ([http://weblrn/](http://weblrn/))

Contains full monographs for the most common drugs in clinical use, plus mini monographs covering investigational, less common, combination, nutraceutical and nutritional products. Provides a keyword search engine.


The Pharma In-Use Search database contains over 400,000 unique pharmaceutical trademarks and tradenames that are used in about 50 countries worldwide. The data is provided under license by IMS HEALTH.

11. **Natural Medicines Comprehensive Databases** ([http://weblrn/](http://weblrn/))

Contains up-to-date clinical data on the natural medicines, herbal medicines, and dietary supplements used in the western world.

12. **StatRef** ([http://weblrn/](http://weblrn/))

Contains full-text information from approximately 30 texts. Includes tables and references. Among the database titles are: Handbook of Adverse Drug Interactions, Rudolphs Pediatrics, Basic Clinical Pharmacology and Dictionary of Medical Acronyms Abbreviations.


List contains all the recognized USAN stems.

14. **Red Book Pharmacy’s Fundamental Reference**

Contains prices and product information for prescription, over-the-counter drugs, medical devices, and accessories.
15. **Lexi-Comp** ([www.pharmacist.com](http://www.pharmacist.com))

16. **Medical Abbreviations Book**
Contains commonly used medical abbreviations and their definitions.
APPENDICES

Appendix A:

The Medication Error Staff consider the spelling of the name, pronunciation of the name when spoken, and appearance of the name when scripted. DMETS also compare the spelling of the proposed proprietary name with the proprietary and established name of existing and proposed drug products because similarly spelled names may have greater likelihood to sound similar to one another when spoken or look similar to one another when scripted. The Medication Error Staff also examine the orthographic appearance of the proposed name using a number of different handwriting samples. Handwritten communication of drug names has a long-standing association with drug name confusion. Handwriting can cause similarly and dissimilarly spelled drug name pairs to appear very similar to one another and the similar appearance of drug names when scripted has lead to medication errors. The Medication Error Staff apply their expertise gained from root-cause analysis of such medication errors to identify sources of ambiguity within the name that could be introduced when scripting (i.e. “T” may look like “F,” lower case ‘a’ looks like a lower case “u,” etc), along with other orthographic attributes that determine the overall appearance of the drug name when scripted (see detail in Table 1 below). Additionally, since verbal communication of medication names is common in clinical settings, the Medication Error Staff compare the pronunciation of the proposed proprietary name with the pronunciation of other drug names. If provided, DMETS will consider the Applicant’s intended pronunciation of the proprietary name. However, because the Applicant has little control over how the name will be spoken in practice, DMETS also considers a variety of pronunciations that could occur in the English language.

<table>
<thead>
<tr>
<th>Type of similarity</th>
<th>Considerations when searching the databases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Potential causes of drug name similarity</td>
</tr>
<tr>
<td>Look-alike</td>
<td>Similar spelling</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Orthographic similarity</td>
<td>Similar spelling</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Sound-alike</td>
<td>Phonetic similarity</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Appendix B:** Proprietary names used only in Foreign Countries

<table>
<thead>
<tr>
<th>Proprietary Name</th>
<th>Similarity to Nplate</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zylate</td>
<td>Look</td>
<td>India</td>
</tr>
</tbody>
</table>

**Appendix C** Products with no numerical overlap in strength and dose.

<table>
<thead>
<tr>
<th>Nplate (romiplostim)</th>
<th>250 mcg and 500 mcg vials</th>
<th>Usual dose: 2-3 mcg/kg/dose (120 mcg – 300 mcg for weight range of 60-100 kg) subcutaneously weekly.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product name with potential for confusion</td>
<td>Similarity to Proposed Proprietary Name</td>
<td>Strength</td>
</tr>
<tr>
<td>Cylate®</td>
<td>Look</td>
<td>1%</td>
</tr>
<tr>
<td>Look</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

***Note: This is proprietary and confidential information that should not be released to the public.***

16
**Appendix D:** Potential confusing name with numerical overlap in strength or dose

<table>
<thead>
<tr>
<th>Nplate® (Romiplostim)</th>
<th>250 mcg and 500 mcg vials</th>
<th>Usual dose: 2-3 mcg/kg/dose (120 mcg - 300 mcg for weight range of 60-100 kg, subcutaneously or IV)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Failure Mode: Name Confusion</strong></td>
<td>Causing (could be multiple)</td>
<td>Effects: Orthographic differences in the names minimize the likelihood of medication error in the usual practice setting. Refludan® infusion dose 0.15 mg/kg/hour does not overlap with the dose of Nplate. Refludan® likely will have a bolus at the initiation of therapy. <strong>Rationale:</strong> The orthographic differences stem from the fact that Refludan® has two additional letters (eight compared to six) and therefore additional length compared to Nplate. The ‘t’ in Refludan® provides an additional upstroke in the name compared to Nplate. The ‘t’ in Nplate has a cross stroke not present in Refludan®.</td>
</tr>
<tr>
<td>Refludan® (lepirudin) for injection 50 mg vial</td>
<td>Orthographic similarities; ‘n’ is similar to ‘r’, one downstroke ‘p’ vs. ‘f’ near beginning of the name, ‘la’ compared to ‘hu’ followed by an upstroke (‘t’ vs. ‘d’), Numerical overlap in strength (50 mg versus 500 mcg). Dosage form is the same, powder for injection in a vial. Indications relate to thrombocytopenia (anticoagulation for patients with heparin-induced thrombocytopenia vs. ITP) Prescribers the same, (hematologists)</td>
<td></td>
</tr>
</tbody>
</table>
Page(s) Withheld

____ § 552(b)(4) Trade Secret / Confidential

X  § 552(b)(4) Draft Labeling

____ § 552(b)(5) Deliberative Process